2024 Insights: Unmet Needs, Therapeutic Innovations, and Pivotal Findings in Chronic Hand Eczema

As we wrap up the last quarter of 2024, Dermatology Times is reflecting on key insights shared at dermatologic conferences over the past 3 months. While advancements in many disease states have been at top of mind, one in particular that has stood out to our editors is chronic hand eczema. From unmet needs to treatment innovations, listen in as Christopher Bunick, MD, PhD, Raj Chovatiya, MD, PhD, and Alexander Egeberg, MD, PhD, share pearls on the developments being made to better understand the condition.

Navigating Complexities and Unmet Needs of Chronic Hand Eczema

“Chronic hand eczema is defined as hand eczema that occurs for more than 3 months in a year, or relapses twice or more in a given year. Another way to think about chronic hand eczema is that it is a heterogeneous, long-lasting, fluctuating inflammatory skin disease of the hands,” said Christopher Bunick, MD, PhD, in a recent interview with Dermatology Times.

Bunick, associate professor of dermatology and translational biomedicine at the Yale University School of Medicine in New Haven, Connecticut, and Dermatology Times’ 2024 Winter Editor in Chief discussed chronic hand eczema’s (CHE) significant impact on quality of life in patients, the key differences between CHE and atopic dermatitis on the hand, and the lack of FDA-approved treatments in the US.

Read the full summary here

Raj Chovatiya, MD, PhD: Current Disease States and Early Career Controversies

Following his presentations at the 44th annual Fall Clinical Dermatology Conference held in Las Vegas, Nevada from October 24 to 27, Raj Chovatiya, MD, PhD, spoke with Dermatology Times on his presentations titled, “Chronic Hand Eczema: Pathophysiology, Diagnosis, and Disease
Management” and “Early Career Controversies”.

Read the full summary here

Alexander Egeberg, MD, PhD, Shares Key Findings on Chronic Hand Eczema and Atopic Dermatitis

“As a company, we can do a lot of innovation, but we can only really help patients if we're actually actively able to communicate some of the science and discoveries that we've done. Because if we're not able to tell about all the innovations we've made, then clinicians will not be aware, and that will not benefit patients,” said Alexander Egeberg, MD, PhD, in an interview with Dermatology Times.

Egeberg, a board-certified dermatologist and the Head of Global Medical Affairs at LEO Pharma, recently highlighted LEO Pharma’s dedication to advancing dermatologic care through innovative treatments and research. He shared insights from the 2024 European Academy of Dermatology and Venereology (EADV) conference, where LEO Pharma presented its largest portfolio of studies on chronic hand eczema and atopic dermatitis, including the promising results of delgocitinib cream and real-world evidence on tralokinumab. Egeberg detailed 7 key takeaways, ranging from the significant quality-of-life impact of chronic skin diseases to the exciting potential of novel therapies in addressing previously unmet needs for dermatology patients worldwide.

Read the full summary here